Understanding The Cooper Companies (COO) Reliance on International Revenue

The Cooper Companies (COO) reported total revenue of $1 billion for the quarter, a 6.3% year-over-year increase, with EMEA and Asia Pacific regions contributing $248.6 million and $138.6 million, respectively, both exceeding analyst expectations. Wall Street anticipates continued growth, projecting total revenue of $1.07 billion for the current fiscal quarter and $4.12 billion for the full year, with EMEA and Asia Pacific expected to contribute significantly; however, COO's stock has declined nearly 20% over the past three months, contrasting with the S&P 500's marginal decline.

Analysis

The Cooper Companies (COO) reported robust operational performance for the quarter ending April 2025, with total revenue increasing 6.3% year-over-year to $1 billion. International segments were pivotal to this growth, as EMEA contributed $248.6 million (24.80% of total revenue) and Asia Pacific added $138.6 million (13.83%), surpassing Wall Street consensus estimates by +1.97% and +1.47% respectively. Analyst projections indicate continued positive momentum, with expectations for current quarter total revenue to reach $1.07 billion, a 6.7% year-over-year rise, and full-year revenue to hit $4.12 billion, up 5.7%. International markets are anticipated to uphold their significant revenue share. Despite these strong fundamental indicators and positive outlook for its core business, COO's stock has experienced a significant downturn, falling 17% in the preceding four weeks and 19.7% over the past three months, markedly underperforming the S&P 500 and the broader Zacks Medical sector. This divergence is reflected in its Zacks Rank #3 (Hold), suggesting the stock may perform in line with the market, balancing its operational strengths against recent price weakness and other unstated market concerns.

Key Decisions for Investors

• Investors should scrutinize the factors contributing to the pronounced disconnect between The Cooper Companies' solid revenue growth and international market outperformance, and its recent significant stock price decline.
• Closely monitor upcoming earnings releases and management commentary for continued strength in international revenue, insights into the stock's valuation pressures, and any updates regarding currency fluctuations or geopolitical risks pertinent to its global operations.
• Evaluate the current valuation in light of the stock's near 20% three-month decline and Zacks #3 (Hold) rating, considering whether the operational strength justifies a potential entry point, while remaining cognizant of prevailing negative sentiment and the need for clarity on domestic market performance and overall profitability trends.